ViroGates AS (FRA:EP2) Total Equity: €2.25 Mil (As of Mar. 2026)


FRA:EP2 ViroGates AS FRA:EP2
44 GF Score
Price €1.45
GF Value €0.90
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Total Equity?

ViroGates AS FRA:EP2 +2.84% 44 Total Equity is €2.25 Mil as of Mar. 2026. GuruFocus rates FRA:EP2 with a GF Score™ of 44/100 and a GF Value™ of €0.90. The stock has 2 warning signs investors should review.

ViroGates AS's total equity for the quarter that ended in Mar. 2026 was €2.25 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ViroGates AS Total Equity Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Total Equity Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.21 2.16 2.28 1.45 2.60

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.64 0.38 2.60 2.25
FRA:EP2
44GF Score
ViroGates AS FRA:EP2
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ViroGates AS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=4.096-1.498
=2.60

ViroGates AS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3.582-1.335
=2.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €2.25 Mil mean?
ViroGates AS (FRA:EP2) has a Total Equity of €2.25 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ViroGates AS and its competitors.
Is ViroGates AS's Total Equity too high?
ViroGates AS's current Total Equity is €2.25 Mil. Overall, ViroGates AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Total Equity compare to ABT and SYK?
ViroGates AS's Total Equity of €2.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ViroGates AS and its competitors. ViroGates AS's current Total Equity is €2.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
ViroGates AS (FRA:EP2) has a current Total Equity of €2.25 Mil. The stock's GF Value™ is €0.90, compared to a current price of €1.45 — trading 61.1% above its estimated fair value. The current Total Equity is €2.25 Mil. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Total Equity is €2.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (FRA:EP2) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.

Key valuation signals for FRA:EP2:

  • Total Equity: €2.25 Mil
  • GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Other Exchanges VIRO:Denmark
Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for FRA:EP2

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.45
Price
€0.90
GF Value